The France Journal
SEE OTHER BRANDS

The top news stories from France

The France Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The France Journal.

Press releases published on May 30, 2025

Présentation du bracelet chrétien Tap2Read : un bracelet innovant pour des inspirations quotidiennes

Présentation du bracelet chrétien Tap2Read : un bracelet innovant pour des inspirations quotidiennes

Présentation du bracelet chrétien Tap2Read : un bracelet innovant pour des inspirations quotidiennes IKEJA, LAGOS, NIGERIA, May 30, 2025 /⁨EINPresswire.com⁩/ -- Dans un monde rempli d’incertitude, de stress, d’anxiété, de dépression et de distractions, …

TravelingWiki's Jonathan Sutter Cited w/United Airlines, Airbus & Emirates as Leading Challenge to Existing Travel Norms

TravelingWiki's Jonathan Sutter Cited w/United Airlines, Airbus & Emirates as Leading Challenge to Existing Travel Norms

TravelingWiki CEO Jonathan Sutter has been named as the leading compelling antithetical to the status quo in Autism …

Soft Trim Interior Market to Hit USD 10.5 Billion by 2035, Driven by Premium Comfort and Eco-Friendly Materials

Soft Trim Interior Market to Hit USD 10.5 Billion by 2035, Driven by Premium Comfort and Eco-Friendly Materials

Soft trim interior market driven by growing demand for premium comfort, eco-friendly materials, and enhanced vehicle aesthetics. NEWARK, DE, UNITED STATES, May 30, 2025 /⁨EINPresswire.com⁩/ -- The Automotive Soft Trim Interior Materials Market is poised …

TSplus Releases Server Monitoring Version 6 – A Major Step Forward in Remote Infrastructure Management

TSplus Releases Server Monitoring Version 6 – A Major Step Forward in Remote Infrastructure Management

PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- TSplus is proud to announce the official release of Server Monitoring Version 6, a major upgrade that reinforces its commitment to providing powerful and user-friendly tools for IT professionals managing remote …

ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Communiqué de mise à disposition des documents préparatoires à l'assemblée générale

ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Communiqué de mise à disposition des documents préparatoires à l'assemblée générale

ADC SIIC Société Européenne au capital de 20 572 093,32 euros Siège social : Avenue de l'Astronomie, 9 – 1210 Saint-Josse-Ten-Noode (Belgique) RPM Bruxelles – Section francophone 0526.937.652 Bruxelles, le 30 mai 2025 Informations réglementées : Communiqué …

ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Avis de convocation

ALLIANCE DEVELOPPEMENT CAPITAL SIIC: Avis de convocation

ALLIANCE DEVELOPPEMENT CAPITAL SIIC SOCIETE EUROPEENNE Avenue de l'Astronomie, 9 1210 Saint-Josse-ten-Noode (Belgique) RPM Bruxelles - Section francophone- 0526.937.652 CONVOCATION À L'ASSEMBLEE GENERALE ORDINAIRE DES ACTIONNAIRES ET À UNE ASSEMBLEE …

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still alive 80% of patients treated with …

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided …

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO

Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO

L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des exacerbations modérées ou sévères chez …

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service